$775 Million is the total value of Johnson & Johnson Innovation - JJDC, Inc.'s 15 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
LUNG | New | Pulmonx Corp | $389,000 | – | 5,639 | +100.0% | 0.05% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-09
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Arrowhead Pharmaceuticals, Inc. | 7 | Q2 2021 | 74.6% |
PROTAGONIST THERAPEUTICS INC. | 7 | Q2 2021 | 11.2% |
BIOMX INC. | 7 | Q2 2021 | 8.1% |
PHASEBIO PHARMACEUTICALS, INC. | 7 | Q2 2021 | 3.5% |
ALDEYRA THERAPEUTICS, INC. | 7 | Q2 2021 | 1.2% |
CASTLIGHT HEALTH INC. | 7 | Q2 2021 | 0.4% |
SENSEONICS HOLDINGS, INC. | 7 | Q2 2021 | 0.2% |
CATALYST BIOSCIENCES, INC. | 7 | Q2 2021 | 0.2% |
TRACON PHARMACEUTICALS, INC. | 7 | Q2 2021 | 0.1% |
MEIRAGTX HOLDINGS PLC | 6 | Q2 2021 | 21.2% |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-29 |
13F-NT | 2024-08-09 |
13F-NT | 2024-05-10 |
3 | 2024-04-10 |
4 | 2024-03-06 |
13F-NT | 2024-02-14 |
3/A | 2024-02-02 |
4/A | 2024-02-02 |
SC 13G | 2023-11-16 |
13F-NT | 2023-11-09 |
View Johnson & Johnson Innovation - JJDC, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.